Trials / Completed
CompletedNCT00240019
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Addition of furosemide 20 mg oral bid to baseline regimen |
Timeline
- Start date
- 2003-12-01
- Completion
- 2006-04-01
- First posted
- 2005-10-17
- Last updated
- 2006-10-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00240019. Inclusion in this directory is not an endorsement.